ArticlePituitary2026
AIP expression and imaging findings in somatotroph adenomas after pre-operative lanreotide therapy for acromegaly.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSomatostatin analogues (SSAs) have been demonstrated to aid hormonal control and reduce tumour size in patients with growth hormone (GH)-secreting macroadenomas. These tumours have varying genetic profiles and do not all respond to SSA therapy. Patients with variants in the aryl-hydrocarbon-receptor interactive protein gene (AIP) often have young-onset invasive tumours with poor SSA response. We sought to assess whether protein expression of AIP could be correlated to lanreotide response and imaging characteristics.
methodsEligible patients recruited to a trial of lanreotide therapy (120 mg Lanreotide Autogel® monthly for 12 months) had their hormone profile (GH, IGF-1) and pituitary MRI monitored at 3, 6 and 12 months. Surgery was planned after 12 months, or earlier if deemed necessary. Immunohistochemical AIP-staining was performed and an AIP-staining score calculated based on AIP expression across 10 random areas.
results20 patients were recruited: 16 had AIP-staining following surgery, 19 full hormone profiles. A reduction of IGF-1 at 12 months was observed in 10 patients (mean 1.09 x upper limit of normal), whilst 6 patients were considered “not biochemically controlled (at 12 months)” (mean 2.51 x upper limit of normal) and 3 required early surgery. A significant correlation between AIP-staining score and %-reduction in IGF-1 was seen. The mean tumour shrinkage over 12 months (25%) was non-significantly greater in patients with high versus low AIP-staining.
conclusionHigher expression of AIP after pre-operative SSA treatment was correlated with better hormone response to lanreotide. Future exploration of AIP expression in matched SSA-treated and non-treated patients would aid understanding of mechanisms involved.
Indexed as
Identifiers
41880072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.